Summary
Overall survival enhancement for patients with gastrointestinal malignancies is most likely to come from the integration of active systemic drug therapies into combined modality programs, applied in the surgical adjuvant or locoregional disease setting. Recent results of chemotherapy trials in advanced disease are discussed with emphasis placed on regimens that appear to be likely candidates for future early-stage disease studies. The ultimate success of this overall strategy depends heavily on identification of new active chemotherapeutic agents. Meticulous disease-oriented phase II testing of all new agents in gastrointestinal cancers is critical to this effort.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bitran J, Desser R, Kozloff M, Billings A (1979) Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, adriamycin and mitomycin-C (FAM). Cancer Treat Rep 63:2049–2051
Brown JC, Bruckner HW, Storch J, Chamberlin K, Pressman PI (1980) Combination chemotherapy for pancreatic cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 21:420
Engstrom P, Maclntyre J, Douglass H, Carbone P (1978) Combination chemotherapy of advanced bowel cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:384
Gastrointestinal Tumor Study Group (1979) Phase II-III studies in advanced gastric cancer. Cancer Treat Rep 63:1871–1876
Haegele LA, Conroy JF, Brodsky I, Kahn SB (1979) Dimethyl triazene imidazole carboxamide (DTIC) and mitomycin-C in the treatment of advanced colon carcinoma. Proc Am Assoc Cancer Res Am Soc Clin Oncol 20:342
Kemeny N, Yagoda A, Golbey R (1980) A prospective randomized study of methyl-CCNU, 5-fluorouracil and vincristine (MOF) vs MOF plus streptozotocin (MOF-Strep) in patients with metastatic colorectal carcinoma. Proc Am Assoc Cancer Res Am Soc Clin Oncol 21:417
Macdonald JS, Schein P, Ueno W, Woolley PV (1979) 5-Fluorouracil, mitomycin-C and adriamycin (FAM): A new combination chemotherapy program for advanced gastric carcinoma. Cancer 44:42–47
Moertel CG, Lavin P (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1863–1869
Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) Therapy of advanced gastrointestinal cancer with a combination of 5-FU, methyl-CCNU and vincristine. J Natl Cancer Inst 54: 69–71
O’Connell M, O’Fallon J, Lavin P, Moertel C, Bruckner H, Douglass H, Livestone E, Lokich J, Mitchell M, for the Gastrointestinal Tumor Study Group (1980) A comparative assessment of combination chemotherapy in advanced gastric carcinoma. Proc Am Assoc Cancer Res Am Soc Clin Oncol 21:420
Panettiere F, Heilbrun L (1979) Comparison of two different combinations of adriamycin, mitomycin-C and 5-FU in the management of gastric carcinoma: A SWOG study. Proc Am Assoc Cancer Res Am Soc Clin Oncol 20: 315
Silverberg E (1980) Cancer statistics 1980. CA 30:39
Smith FP, Macdonald JS, Woolley PV, Hoth DF, Smythe TA, Lichtenfeld L, Levin B, Schein P (1979) Phase II evaluation of FAM in advanced pancreatic cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 20:415
Wiggans G, Woolley PV, Macdonald JS et al. (1978) Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387–391
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Kisner, D.L., Macdonald, J.S. (1982). Chemotherapy of Metastatic Gastrointestinal Cancers: Prospects for Future Adjuvant Systemic Therapies. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_46
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_46
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive